Published in Am J Ophthalmol on January 01, 2002
Protein Profile of Immunoregulatory Factors in Diabetic Cataract | NCT01832311
Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol (2005) 1.95
Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol (2004) 1.92
Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol (2011) 1.46
Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab (2013) 1.34
Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol (2013) 1.23
Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes. Exp Eye Res (2009) 1.23
Interleukin-6 as a photoreceptor neuroprotectant in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci (2008) 1.06
New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye (Lond) (2012) 1.04
Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci (2006) 1.03
Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol (2012) 1.01
Serum TNF-alpha level predicts nonproliferative diabetic retinopathy in children. Mediators Inflamm (2007) 1.00
Short-term results of intravitreal dexamethasone implant (OZURDEX(®)) in treatment of recalcitrant diabetic macular edema: A case series. Oman J Ophthalmol (2012) 1.00
Soluble mediators of diabetic macular edema: the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema. Curr Diab Rep (2013) 0.99
Aqueous cytokine and growth factor levels do not reliably reflect those levels found in the vitreous. Mol Vis (2011) 0.97
Role of IL-6 in angiotensin II-induced retinal vascular inflammation. Invest Ophthalmol Vis Sci (2009) 0.97
Contribution of microglia-mediated neuroinflammation to retinal degenerative diseases. Mediators Inflamm (2015) 0.96
Anti-VEGF for the management of diabetic macular edema. J Immunol Res (2014) 0.92
Increased intraocular insulin-like growth factor-I triggers blood-retinal barrier breakdown. J Biol Chem (2009) 0.90
Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II. Br J Ophthalmol (2004) 0.89
A prospective, randomized comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab (avastin) in diffuse diabetic macular edema. Middle East Afr J Ophthalmol (2010) 0.87
Study of 27 Aqueous Humor Cytokines in Type 2 Diabetic Patients with or without Macular Edema. PLoS One (2015) 0.86
Visual acuity comparison of vitrectomy with and without internal limiting membrane removal in the treatment of diabetic macular edema. Int Ophthalmol (2006) 0.86
Comparison of aqueous concentrations of angiogenic and inflammatory cytokines based on optical coherence tomography patterns of diabetic macular edema. Indian J Ophthalmol (2015) 0.86
Diabetic macular edema: New promising therapies. World J Diabetes (2013) 0.85
PPAR-gamma, Microglial Cells, and Ocular Inflammation: New Venues for Potential Therapeutic Approaches. PPAR Res (2008) 0.85
Functions of Müller cell-derived vascular endothelial growth factor in diabetic retinopathy. World J Diabetes (2015) 0.85
Targeting Neovascularization in Ischemic Retinopathy: Recent Advances. Expert Rev Ophthalmol (2013) 0.84
Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes. Angiogenesis (2016) 0.84
Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema. Clin Ophthalmol (2014) 0.84
Endoplasmic reticulum stress and inflammation: mechanisms and implications in diabetic retinopathy. J Ocul Biol Dis Infor (2012) 0.83
Intravitreal bevacizumab for treatment of diabetic macular edema. Korean J Ophthalmol (2009) 0.81
Intravitreous VEGF-A in eyes with massive vitreous hemorrhage. Graefes Arch Clin Exp Ophthalmol (2011) 0.81
Clinical trials on corticosteroids for diabetic macular edema. World J Diabetes (2013) 0.81
Changes in foveal thickness after vitrectomy for macular edema with branch retinal vein occlusion and intravitreal vascular endothelial growth factor. Int Ophthalmol (2008) 0.81
Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). Eye (Lond) (2015) 0.81
Systemic medical management of diabetic retinopathy. Middle East Afr J Ophthalmol (2013) 0.80
Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus. Am J Ophthalmol (2009) 0.79
Pathophysiological characteristics of diabetic ocular complications in spontaneously diabetic torii rat. J Ophthalmol (2010) 0.79
The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice. Indian J Ophthalmol (2007) 0.78
Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK. Drugs Aging (2014) 0.78
A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series. Clin Ophthalmol (2015) 0.78
Efficacy of single-dose dexamethasone implantation in patients with persistent diabetic macular edema. Int Ophthalmol (2015) 0.77
Population pharmacokinetics of pegaptanib sodium (Macugen(®)) in patients with diabetic macular edema. Clin Ophthalmol (2015) 0.77
Nicotine exposure exacerbates development of cataracts in a type 1 diabetic rat model. Exp Diabetes Res (2012) 0.77
Age-dependent alteration of intraocular soluble heparan sulfate levels and its implications for proliferative diabetic retinopathy. Mol Vis (2013) 0.77
An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol (2016) 0.77
Effects of Minocycline on Urine Albumin, Interleukin-6, and Osteoprotegerin in Patients with Diabetic Nephropathy: A Randomized Controlled Pilot Trial. PLoS One (2016) 0.77
Review of therapeutic advances in diabetic retinopathy. Ther Adv Endocrinol Metab (2011) 0.77
Glycobiology of ocular angiogenesis. Glycobiology (2014) 0.76
Ranibizumab for diabetic macular edema difficult to treat with focal/grid laser. Graefes Arch Clin Exp Ophthalmol (2010) 0.76
Efficacy of intravitreal anti-vascular endothelial growth factor or steroid injection in diabetic macular edema according to fluid turbidity in optical coherence tomography. Korean J Ophthalmol (2014) 0.76
The macular function and structure in patients with diabetic macular edema before and after ranibizumab treatment. Doc Ophthalmol (2016) 0.75
Sugar creates a sticky business: round up the usual suspects. Am J Pathol (2002) 0.75
An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema. Clin Ophthalmol (2014) 0.75
Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents. J Ophthalmol (2016) 0.75
Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease. Clin Ophthalmol (2013) 0.75
Intravitreal injection of Bevacizumab in diabetic macular edema. Pak J Med Sci (2015) 0.75
Corticosteroid Treatment in Diabetic Macular Edema. Turk J Ophthalmol (2017) 0.75
Relation between macular morphology and treatment frequency during twelve months with ranibizumab for diabetic macular edema. PLoS One (2017) 0.75
The role of aflibercept in the management of diabetic macular edema. Drug Des Devel Ther (2015) 0.75
Use of intravitreal triamcinolone in the treatment of macular edema related to retinal vein occlusion. Open Ophthalmol J (2008) 0.75
Outer retinal tubulation in diabetic macular edema following anti-VEGF treatment. Eye Vis (Lond) (2015) 0.75
Diabetic macular edema, retinopathy and age-related macular degeneration as inflammatory conditions. Arch Med Sci (2016) 0.75
Association of systemic comorbidity in diabetic serous macular detachment and comparison of various combination therapies in its management. Clin Ophthalmol (2013) 0.75
Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema. PLoS One (2017) 0.75
The clinical utility of aflibercept for diabetic macular edema. Diabetes Metab Syndr Obes (2015) 0.75
Aflibercept versus ranibizumab for treating persistent diabetic macular oedema. Int Ophthalmol (2015) 0.75
Laser flare-cell photometer: principle and significance in clinical and basic ophthalmology. Jpn J Ophthalmol (2016) 0.75
Evaluation of foveal photoreceptor layer in eyes with macular edema associated with branch retinal vein occlusion after ozurdex treatment. Int Ophthalmol (2016) 0.75
The genome sequence of silkworm, Bombyx mori. DNA Res (2004) 4.27
Ultrafine membrane compartments for molecular diffusion as revealed by single molecule techniques. Biophys J (2004) 3.54
Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol (2004) 3.28
Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol (2005) 2.32
Improvement in cognitive impairment after cataract surgery in elderly patients. J Cataract Refract Surg (2004) 2.24
Subconjunctival hemorrhage and conjunctivochalasis. Ophthalmology (2009) 2.20
Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol (2005) 1.95
Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol (2004) 1.92
Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology (2009) 1.91
Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology (2003) 1.83
The long-term effects of self-management education for patients with type 2 diabetes on glycemic control: response to Norris et al. Diabetes Care (2002) 1.78
Effect of perioperative glycemic control in progression of diabetic retinopathy and maculopathy. Arch Ophthalmol (2006) 1.64
Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion. Br J Ophthalmol (2010) 1.63
Vitrectomy for diabetic macular edema with and without internal limiting membrane removal. Ophthalmologica (2005) 1.59
Recent causes of subconjunctival hemorrhage. Ophthalmologica (2009) 1.58
HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant (2003) 1.57
Adjusting intraocular lens power for sulcus fixation. J Cataract Refract Surg (2003) 1.48
Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology (2009) 1.44
Association of Treatment for Hyperlipidemia with Decreased Total Mortality in Japanese Individuals: the Yamagata (Takahata) Study. J Atheroscler Thromb (2015) 1.44
Human corneal endothelial cell precursors isolated by sphere-forming assay. Invest Ophthalmol Vis Sci (2005) 1.43
Intoxication with over-the-counter antitussive medication containing dihydrocodeine and chlorpheniramine causes generalized convulsion and mixed acidosis. Intern Med (2008) 1.41
Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol (2002) 1.36
Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology (2006) 1.33
Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema. Am J Ophthalmol (2003) 1.27
Cup-shaped choroidal excavation detected by optical coherence tomography: a case report. Retin Cases Brief Rep (2010) 1.25
Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology (2008) 1.23
Analysis of novel disease-related genes in bronchial asthma. Cytokine (2002) 1.22
Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology (2005) 1.20
Delphilin: a novel PDZ and formin homology domain-containing protein that synaptically colocalizes and interacts with glutamate receptor delta 2 subunit. J Neurosci (2002) 1.17
In vivo proliferation of postmitotic cochlear supporting cells by acute ablation of the retinoblastoma protein in neonatal mice. J Neurosci (2010) 1.17
Cardiovascular risk factors and retinal microvascular signs in an adult Japanese population: the Funagata Study. Ophthalmology (2006) 1.17
IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol (2003) 1.17
Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. Eur J Ophthalmol (2010) 1.16
Age differences in cyclin-dependent kinase inhibitor expression and rb hyperphosphorylation in human corneal endothelial cells. Invest Ophthalmol Vis Sci (2006) 1.15
Clinicopathological analysis of malignant eyelid tumor cases at Yamagata university hospital: statistical comparison of tumor incidence in Japan and in other countries. Jpn J Ophthalmol (2005) 1.11
High-dose steroid therapy for idiopathic optic perineuritis: a case series. J Med Case Rep (2010) 1.11
Proteome analysis of human vitreous proteins. Mol Cell Proteomics (2003) 1.11
Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular oedema and central retinal vein occlusion. Acta Ophthalmol (2010) 1.07
Hyaluronan fragments induce endothelial cell differentiation in a CD44- and CXCL1/GRO1-dependent manner. J Biol Chem (2005) 1.06
Questionnaire survey on periodic ocular examination in Japanese diabetic patients. Am J Ophthalmol (2003) 1.06
Distribution of precursors in human corneal stromal cells and endothelial cells. Ophthalmology (2007) 1.05
The activity of hyaluronan synthase 2 is regulated by dimerization and ubiquitination. J Biol Chem (2010) 1.04
Upregulation of IL-13 concentration in vivo by the IL13 variant associated with bronchial asthma. J Allergy Clin Immunol (2002) 1.03
Predicting macro- and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care (2013) 1.02
Sphere formation and expression of neural proteins by human corneal stromal cells in vitro. Invest Ophthalmol Vis Sci (2005) 1.02
Prestin-prestin and prestin-GLUT5 interactions in HEK293T cells. Dev Neurobiol (2007) 1.02
Autologous transplantation of conjunctival epithelial cells cultured on amniotic membrane in a rabbit model. Mol Vis (2007) 1.01
Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. Graefes Arch Clin Exp Ophthalmol (2010) 1.00
Corneal stromal and endothelial cell precursors. Cornea (2006) 1.00
Neuroprotective effects of erythropoietin on glutamate and nitric oxide toxicity in primary cultured retinal ganglion cells. Brain Res (2005) 1.00
Functional-morphologic correlates in patients with branch retinal vein occlusion and macular edema. Retina (2011) 1.00
Association of inflammatory factors with macular edema in branch retinal vein occlusion. JAMA Ophthalmol (2013) 0.99
Vitreous inflammatory factors in macular edema with central retinal vein occlusion. Jpn J Ophthalmol (2011) 0.98
Relationship of macular microcirculation and retinal thickness with visual acuity in diabetic macular edema. Ophthalmology (2007) 0.98
The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma. J Ocul Pharmacol Ther (2005) 0.97
Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy. J Cataract Refract Surg (2002) 0.97
Increase of aqueous inflammatory factors in macular edema with branch retinal vein occlusion: a case control study. J Inflamm (Lond) (2010) 0.97
Inflammatory factors in major and macular branch retinal vein occlusion. Ophthalmologica (2012) 0.94
Management of type 2 diabetics requiring panretinal photocoagulation and cataract surgery. J Cataract Refract Surg (2008) 0.94
Conjunctivochalasis and contact lenses. Am J Ophthalmol (2009) 0.94
Changes of conjunctivochalasis with age in a hospital-based study. Am J Ophthalmol (2008) 0.94
Regulation mechanisms of retinal pigment epithelial cell migration by the TGF-beta superfamily. Acta Ophthalmol Scand (2003) 0.93
Apparent accommodation and corneal wavefront aberration in pseudophakic eyes. Invest Ophthalmol Vis Sci (2002) 0.93
Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Curr Eye Res (2011) 0.93
Relation of diabetic macular edema to cytokines and posterior vitreous detachment. Am J Ophthalmol (2003) 0.93
Body composition is related to increase in plasma adiponectin levels rather than training in young obese men. Eur J Appl Physiol (2005) 0.92
Pigment epithelium-derived factor and vascular endothelial growth factor in branch retinal vein occlusion with macular edema. Graefes Arch Clin Exp Ophthalmol (2010) 0.92